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Abstract
Objective: To evaluate changes of nuclear factor-kappa B (NF-kB) during radioiodine 131 (
131I) therapy and whether NF-kB
inhibition could enhance
131I-induced apoptosis in differentiated thyroid cancer (DTC) cells in a synergistic manner.
Methods: Three human DTC cell lines were used. NF-kB inhibition was achieved by using a NF-kB inhibitor (Bay 11-7082) or
by p65 siRNA transfection. Methyl-thiazolyl-tetrazolium assay was performed for cell viability assessment. DNA-binding
assay, luciferase reporter assay, and Western blot were adopted to determine function and expression changes of NF-kB.
Then NF-kB regulated anti-apoptotic factors XIAP, cIAP1, and Bcl-xL were measured. Apoptosis was analyzed by Western
blot for caspase 3 and PARP, and by flow cytometry as well. An iodide uptake assay was performed to determine whether
NF-kB inhibition could influence radioactive iodide uptake.
Results: The methyl-thiazolyl-tetrazolium assay showed significant decrease of viable cells by combination therapy than by
mono-therapies. The DNA-binding assay and luciferase reporter assay showed enhanced NF-kB function and reporter gene
activities due to
131I, yet significant suppression was achieved by NF-kB inhibition. Western blot proved
131I could increase
nuclear NF-kB concentration, while NF-kB inhibition reduced NF-kB concentration. Western blot also demonstrated
significant up-regulation of XIAP, cIAP1, and Bcl-xL after
131I therapy. And inhibition of NF-kB could significantly down-
regulate these factors. Finally, synergism induced by combined therapy was displayed by significant enhancements of
cleaved caspase 3 and PARP from Western blot, and of Annexin V positively staining from flow cytometry. The iodine uptake
assay did not show significant changes when NF-kB was inhibited.
Conclusion: We demonstrated that
131I could induce NF-kB activation, which would attenuate
131I efficacy in DTC cells. NF-
kB inhibition by Bay 11-7082 or by p65 siRNA transfection was effective in suppressing NF-kB regulated anti-apoptotic
changes and in combined regimen apoptosis was achieved synergistically.
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Introduction
Thyroid nodule is a very common clinical problem and thyroid
cancer is increasingly prevalent nowadays [1]. Differentiated thyroid
cancer (DTC), including papillary and follicular thyroid cancer,
comprises the majority of all thyroid cancers. Although the overall
prognosis for DTC is good if total thyroidectomy and radioiodine
131 (
131I) therapies are applied [2], patients with
131I-refractory
metastases couldonlyachieve a 10% 10-yearsurvivalrate[3,4].And
for some cases, even
131I-avid lesions could not be successfully
controlled by
131I therapy alone [5]. Therefore, development of
novel anti-cancer methods is urgently needed for thyroid cancer.
In recent years, a number of culprit molecular targets have been
identified in DTC carcinogenesis [6,7,8]. Among these, an
emerging body of evidence shows that nuclear factor-kappa B
(NF-kB) plays a crucial role in thyroid cancer, including cancer
development and progression [6,7,9,10,11,12,13,14]. It is also
demonstrated that NF-kB induction by chemotherapy or radio-
therapy could attenuate therapeutic efficacies. And NF-kB
inhibition could promote thyroid cancer cell apoptosis, and to
achieve synergistic effects [8,9,10,11,12]. However, to our
knowledge, there has been no study investigating the relationship
between NF-kB and
131I therapy in DTC, despite the importance
of
131I treatment in DTC management.
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33597Therefore, the purpose of the present research was to evaluate
changes of NF-kB during
131I therapy. And we also aimed to
determine whether combination with a NF-kB inhibitor or small
interference RNA (siRNA) transfection could enhance
131I-
induced apoptosis in DTC in a synergistic manner.
Materials and Methods
Cell culture
The human papillary thyroid carcinoma cell lines KTC-1,
TPC-1 and follicular thyroid carcinoma cell line WRO were
kindly provided by Dr. Shunichi Yamashita and Dr. Norisato
Mitsutake (Department of Molecular Medicine, Atomic Bomb
Disease Institute, Nagasaki University Graduate School of
Biomedical Sciences, Nagasaki, Japan). DTC cells were grown in
Dulbecco’s minimum essential medium (GIBCO BRL, NY, USA)
supplemented with 5% fetal bovine serum (GIBCO BRL, NY,
USA), 1% (w/v) penicillin/streptomycin (Sigma-Aldrich, MO,
USA) and 1 mU/mL thyrotropin (Sigma-Aldrich, MO, USA) in a
5% CO2 humidified atmosphere at 37uC.
Transfection with siRNA
SMARTpool NF-kB p65 siRNAs was commercially designed
by Dharmacon (Dallas, TX, USA). The pool of siRNAs contained
the p65-specific sequences. Scrambled oligonucleotides (sequence
AATTCTCCGAACGTGTCACGT) were chemically synthesized
by SBS GeneTech (Beijing, China) and it was analyzed in a
BLAST search to exclude homology to p65 or other genes [15].
When DTC cells were at 50%–60% confluence, transfection of
p65 SMARTpool siRNAs (100 nmol/L), scrambled oligonucleo-
tides (100 nmol/L) or no oligonucleotide (control) was performed
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) for
6 hours at 37uC in 6-well plates. Following transfection, cells were
grown in new mediums and treated or collected as indicated.
Methyl-thiazolyl-tetrazolium (MTT) assay
DTC cells (100 ml, 6000 cells per well) were seeded to 96-well
plates and incubated for 48 hours before any treatment. Then new
mediums were changed, and
131I (Beijing Atom HighTech,
Beijing, China) or Bay 11-7082 (Sigma-Aldrich, MO, USA) were
added in order to achieve final
131I activity concentrations of 5, 10,
20, 50, 100 and 200 MBq/ml or final Bay 11-7082 concentrations
of 1, 2, 5, 10 and 20 mmol/L in each well. Cells were exposed to
treatments for 48 hours, and 6 replicates were used for each
concentration of either drug. In the control wells DMSO was
added, and final concentration of DMSO did not exceed 0.2% in
any well. After incubation, the cells were treated with MTT
(50 mg/well, Sigma-Aldrich, MO, USA) for 1 hour at 37uC. The
generated formazan was solubilized with 150 ml/well of DMSO,
and the optical densities of the wells were measured at 450 nm
with a Multiskan MS Plate Reader (Labsystems, Helsinki,
Finland).
Proliferation of DTC cell lines after siRNA transfection was also
measured by MTT assay. After transfection with p65 siRNA,
scrambled oligonucleotides or no oligonucleotide control, cells
were transferred as 6 replicates to 96-well plates at a concentration
of 6000 cells per well. After 48 hours of incubation, cells were
treated with or without 20 MBq/ml of
131I for 48 hours. Then
MTT was performed as above.
Preparation of cell extracts
After different treatments, cells were lysed in high salt buffer [9].
For total cell protein, harvested cells were suspended in 100 mlo f
lysis buffer (20 mM Tris-HCl pH 7.5, 1 mM EDTA, 150 mM
NaCl, 0.5% Triton-X, 50 mM NaF, 10 mM sodium pyrophos-
phate, 1 mM sodium orthovanadate and 2 mM phenylmethyi-
sulfonylfluoride) for 20 minutes on ice. Then lysate was centri-
fuged for 15 minutes at 14,000 rpm, and the supernatant was
stored at 280uC until use. For nuclear protein, harvested cells
were suspended in 400 mL of lysis buffer (10 mM HEPES pH 7.9,
10 mM KCl, 1.5 mM MgCl2, 0.5 mM dithiothreitol, 0.5 mM
phenylmethylsulfonylfluoride and 0.1% Nonidet P-40) for 20 min-
utes on ice. Then lysate was centrifuged for 5 minutes at
14,000 rpm. The pellets were resuspended in 40 mL of nuclear
extract buffer (20 mM HEPES pH 7.9, 420 mM NaCl, 1.5 mM
MgCl2, 1 mM dithiothreitol, 0.2 mM EDTA, 0.5 mM phenyl-
methylsulfonylfluoride and 20% glycerol) for 20 minutes on ice.
After centrifuge for 15 minutes at 14,000 rpm, the supernatant
was collected and stored at 280uC until use. Protein concentra-
tions were determined with a bicinchoninic acid assay reagent kit
(Sigma-Aldrich, MO, USA).
DNA-binding assay
The multi-well colorimetric assay for active NF-kB was
performed [9]. Briefly, equal amount of nuclear extracts were
incubated in 96-well plates coated with immobilized oligonucle-
otide containing a NF-kB consensus binding site. NF-kB binding
to the target oligonucleotide was detected with primary antibody
specific to p65 subunit and HRP-conjugated secondary antibody.
For quantification of activity, optical densities were measured at
450 nm with a Multiskan MS Plate Reader.
Luciferase assay
DTC cells were seeded in 24-well plates at 1610
5 cells per well.
The cells were co-transfected with 400 ng of pNF-kB-luc
(Clontech, Mountain View, CA, USA) and 4 ng of pRL-SV40
(Promega, Madison, WI, USA) using Lipofectamine 2000. The
pRL-SV40 plasmid with a cDNA encoding Renilla luciferase was
used as an internal control in each experiment [16]. Cells were
rested for 12 hours after transfection, then incubated with or
without
131I, or with combined therapy of
131I plus Bay 11-7082
for 6 hours. Activities of firefly and Renilla luciferases were
determined sequentially from a single sample with the Dual-
luciferase Reporter Assay system (Promega, Madison, WI, USA)
using a Lumat LB 9507 luminometer (Bethold Technologies, Bad
Wildbad, Germany).
DTC cells were co-transfected with pNF-kB-luc and pRL-SV40
at 24 hours after p65 siRNA or scramble transfection [15]. After
12 hours, the cells were treated with or without 20 MBq/ml of
131I
for 6 hours. Then the reporter gene activities were assayed as
described above.
Western blot
Equal amounts of protein were electrophoresed by SDS-PAGE
in 10% or 15% polyacrylamide gels. Proteins were transferred
onto nitrocellulose membrane (Amersham Biosciences, NJ, USA)
by semidry blotting. Membranes were blocked with Tris-buffered
saline/0.1% Tween 20 (TBST) containing 5% milk for 60 minutes
at room temperature, and then immune-blotted with appropri-
ately diluted primary antibodies at 4uC overnight. After washing
three times with TBST, the blots were incubated with HRP-
conjugated secondary antibody for 60 minutes at room temper-
ature. Then the complexes were visualized in iChemi XR imaging
system (Syngene, MD, USA) by using chemiluminescence reagents
(Millipore, MA, USA). Semi-quantification was performed by
Quantity One Software Version 4.6.2 (Bio-Rad, CA, USA).
Antibodies for NF-kB p65, X-linked inhibitor of apoptosis (XIAP),
B-cell lymphoma extra large (Bcl-xL), cleaved caspase 3, poly-
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Signaling Technology (Beverly, MA, USA). Antibody for cellular
inhibitor of apoptosis 1 (cIAP1) was from R&D Systems
(Minneapolis, MN, USA). And antibody for proliferating cell
nuclear antigen (PCNA) was from BD Transduction Laboratories
(San Jose, CA, USA).
Flow cytometry analysis of apoptotic cells
After 24 hours of different treatments, adherent cells were
harvested by trypsinization, and 4610
5 cells were double stained
with FITC-conjugated annexin V and propidium iodide for
15 minutes at room temperature in a Ca
2+-enriched binding
buffer (BD Pharmingen, CA, USA) and then subjected to
FACSAria
TM flow cytometer (BD Biosciences, CA, USA). FITC
and propidium iodide emissions were detected in FL-1 and FL-3
channels, respectively. Analysis was done with Cell Quest software
(BD Biosciences, CA, USA).
Iodide uptake assay
To determine whether NF-kB inhibition can influence radio-
active iodide uptake, iodide uptake assay was performed as
described by Weiss et al. [17] with some modifications. KTC-1
cells were seeded in 6-well plates and treated with or without
5 mmol/L Bay 11-7082 for 24 hours. Then cells were cultured
with 1 mL new medium per well, containing 37 KBq Na
125I
(Beijing Atom HighTech, Beijing, China), for 1 hour. Afterwards,
the
125I-containing medium was decanted. Then cells were washed
twice with PBS and trypsinized for total cell number counting.
Finally radioactivity of the cells was measured with a c counter
(LKB 1261 Gamma Counter, Wallac, Turku, Finland).
To measure iodide uptake changes after siRNA transfection,
KTC-1 cells transfected with p65 siRNA, scrambled oligonucle-
otides or no oligonucleotide control were transferred to 6-well
plates. Then cells were incubated in the present of Na
125I for
1 hour. Then cell number was counted, and radioactivity was
measured.
Statistical Analysis
All data were presented as mean 6 SD. Statistics were
performed with SPSS 15.0 (SPSS Incorporated, IL, USA).
Differences between groups were analyzed by one-way analysis
of variance (ANOVA) or independent samples T-Test. Least
significant difference (LSD) test was used for multiple comparisons




131I, Bay 11-7082 and siRNA therapies
MTT assay was done after 48 hours of different treatments, and
cell viabilities were calculated based on the total number of cells
grown without any therapeutic intervention. As illustrated in
Figure 1A and 1B, survival rates of all three cell lines showed
inverse relationship to
131I activity concentrations and Bay 11-
7082 dosage concentrations. For the following in vitro experiments,
131I activity concentration and Bay 11-7082 dosage concentration
were determined as 20 MBq/ml and 5 mmol/L, respectively.
Figure 1C showed that, by ANOVA, different treatment
engendered different growth-inhibitory effects (P,0.01). And
LSD revealed significant decrease of viable cells by combination
therapy than by either mono-therapy (P,0.01).
Figure 1D showed that scrambled oligonucleotides transfection
did not inhibit DTC cell proliferation, while siRNA transfection
could achieve obvious inhibitory effects (P,0.05). Moreover,
combination therapy could significantly induce stronger cell death
than either
131I therapy or siRNA transfection (P,0.01).
Effects of different therapies on NF-kB
To examine the effects of
131I on NF-kB, we performed DNA-
binding assay using nuclear extracts from
131I-treated DTC cells
for 6, 24 and 48 hours with untreated cells as control. NF-kB
function increased during the time course of
131I mono-therapy,
reaching peaks at 24-hour time point for KTC-1 and WRO cells.
Figure 1. Cytotoxic effects of
131I, Bay 11-7082 and siRNA therapies on thyroid cancer cells. After exposure to indicated concentrations of
Bay 11-7082 (A), activity concentrations of
131I( B) or combined therapies (C) for 48 hours, cell viabilities were determined by MTT assay. After DTC
cells were treated with no oligonucleotide control, scrambled oligonucleotides or p65 siRNA transfection, cells were transferred to 96-well plates.
Then cells were treated with or without
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reduced NF-kB function (Figure 2A). In the above three time
points, significant NF-kB inhibition was shown by T-Test in the
combined therapies than
131I mono-therapies in all three cell lines
(P,0.01). DTC cells were also transfected with p65 siRNA,
scrambled oligonucleotides or no oligonucleotide control. Then
three groups of all the cell lines were exposed to
131I for 24 hours.
Although NF-kB function was strongly induced by
131I in both
control and scramble groups, significant suppression could be
obtained by p65 siRNA transfection (Figure 2B) in all three cell
lines (P,0.01).
NF-kB responsive promoter activity was performed as well
(Figure 3). We found that
131I significantly enhanced the NF-kB
reporter gene activities, to about 2.5, 1.7 and 3.0 folds in KTC-1,
TPC-1 and WRO cell lines (P,0.05). Nevertheless, combination
with Bay 11-7082 could inhibit NF-kB functions to about 0.16,
0.14 and 0.24 folds of the induced levels in KTC-1, TPC-1 and
WRO cell lines (P,0.01). And p65 siRNA transfection could
reduce NF-kB functions to nearly 0.14, 0.14 and 0.26 folds of the
induced levels respectively (P,0.01).
Next we examined nuclear NF-kB protein levels 6 hours after
different treatments by Western blot (Figure 4). The amounts of
p65 increased in
131I groups in all the cell lines, but suppressed
obviously when Bay 11-7082 was added in the combination
therapy. The similar results were obtained by p65 siRNA
transfection, while scrambled oligonucleotides transfection could
not achieve such effects.
Effects of different therapies on NF-kB regulated anti-
apoptotic factors
As being potent apoptosis inhibitors, XIAP, cIAP1 and Bcl-xL
are target genes positively regulated by NF-kB [7,18]. We tested
what influences different treatments could inflict on them by
Western blot, using KTC-1 as a representative cell line (Figure 5).
Despite certain basal levels of XIAP, cIAP1 and Bcl-xL,
131I
increased XIAP to 5.5–5.7 folds, cIAP1 to 4.8–6.7 folds and Bcl-
xL to 3.6–5.1 folds, respectively. However, after combination with
Bay 11-7082, XIAP, cIAP1 and Bcl-xL protein expressions were
markedly reduced to 0.09, 0.10 and 0.17 folds of the enhanced
levels respectively. After p65 siRNA transfection, these protein
expressions were significantly inhibited to 0.07, 0.06 and 0.10 folds
respectively. ANOVA and LSD revealed significant increases of
these factors in
131I groups than in control groups (P,0.01), and
significant decreases of them in combination groups than in
131I
groups (P,0.01).
Synergistic effects detected in combination therapies
First, Western blot was applied to detect changes of caspase 3 (a
key apoptosis executioner) and PARP (a main target of caspase 3).
We showed that although any intervention could induce cleavages
of caspase 3 (subunits p19 and p17) and PARP (p89), their levels
increased significantly further by combined treatments (Figure 6).
In Table 1, ANOVA and LSD showed significant enhancements
in combined therapies than in mono-therapies (P,0.05). Then, to
further confirm the effects on apoptosis, double staining flow
cytometry was performed. Results showed that while any therapy
could induce apoptosis, combined treatments increased apoptosis
synergistically due to significant enhancements of Annexin V
positively stained cells (Figure 7 and Table 1).
Iodide uptake in DTC cells under NF-kB blocking
To determine whether NF-kB pathway inhibition influences
iodine uptake, we tested radioactive iodine uptake changes with or
without NF-kB inhibition by Bay 11-7082 or p65 siRNA
transfection. Figure 8 demonstrated that there were only slight
changes after therapeutic interventions, no significant differences
were observed (P.0.05), which indicated that NF-kB did not
control iodine uptake in KTC-1 cells.
Figure 2.
131I-induced NF-kB activation can be reduced by Bay 11-7082 or p65 siRNA treatments. (A) DTC cells were treated either with
131I (20 MBq/ml) or in combination with Bay 11-7082 (5 mmol/L) for 6, 24 and 48 hours. Nuclear extracts were prepared, and DNA-binding assay was
done. (B) DTC cells were treated with no oligonucleotide control, scrambled oligonucleotides or p65 siRNA transfection. Then cells were exposed to
131I for 24 hours, and DNA-binding assay was performed. Similar results were obtained in three independent experiments.
doi:10.1371/journal.pone.0033597.g002
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The most effective post-surgical treatment of DTC lesions is
131I
therapy, due to the inherent ability of thyroid cancer cells to
concentrate iodine.
131I emits short pathlength (0.5–2.2 mm) b-
radiation that is cytotoxic to the cells, which is intrinsically very
similar to external radiotherapy. However, this methodology is
ineffective in patients whose tumors no longer concentrate
131I
efficiently [4,19,20]. We tested our hypothesis in this study, that
NF-kB could be an important factor regulating the anti-apoptotic
process during
131I therapy. NF-kB has been shown to play an
important role in many types of cancer [14] including thyroid
cancer [7,8,13,21,22], which heralded searches for drugs capable
of suppressing NF-kB activity [7,18]. Till now, a number of NF-kB
inhibitors have been demonstrated to induce thyroid cancer cell
apoptosis, for instance, SN50, DHMEQ, bortezomib and Bay 11-
Figure 3. Repoter gene activity changes after different
treatments. (A) DTC cells were transfected with pNF-kB-luc, and
pRL-SV40 served as an internal control. After 12 hours, cells were left
untreated or incubated with
131I (20 MBq/ml), or in combination with
Bay 11-7082 (5 mmol/L) for 6 hours. NF-kB activation was detected by
luciferase reporter assay. (B) At 24 hours after transfection with
scrambled oligonucleotides or p65 siRNA, cells were co-transfected
with pNF-kB-luc and pRL-SV40. After 12 hours, cells were left untreated
or treated with
131I (20 MBq/ml) for 6 hours. Then luciferase reporter
assay was performed. Similar results were obtained in three indepen-
dent experiments.
doi:10.1371/journal.pone.0033597.g003
Figure 4. NF-kB protein level changes by different therapies.
DTC cells were left untreated as controls (A), or treated with 20 MBq/ml
131I( B) or in combination with 5 mmol/L Bay 11-7082 (C) for 6 hours.
Then nuclear protein extracts were examined for NF-kB p65 by Western
blot. In the second set of experiments, control cells were left untreated
(D). After no oligonucleotide (E), scrambled oligonucleotides (F) or p65
siRNA (G) transfection, DTC cells were treated with
131I (20 MBq/ml) for
6 hours. Then nuclear protein levels of NF-kB p65 were analyzed. PCNA
was used as a loading control for nuclear proteins. Similar results were
obtained in three independent experiments.
doi:10.1371/journal.pone.0033597.g004
Figure 5. Effects of different treatments on NF-kB regulated
anti-apoptotic factors. KTC-1 cells were left untreated as controls (A),
or treated with 20 MBq/ml
131I( B) or in combination with 5 mmol/L Bay
11-7082 (C) for 24 hours. Then whole cell lysates were examined by
Western blot for XIAP, cIAP1 and Bcl-xL. In the second set of
experiments, control cells were left untreated (D). After no oligonucle-
otide (E), scrambled oligonucleotides (F) or p65 siRNA (G) transfection,
KTC-1 cells were treated with
131I (20 MBq/ml) for 24 hours. Then
protein levels of XIAP, cIAP1 and Bcl-xL were studied. b-actin was used
as a loading control. Similar results were obtained in three independent
experiments.
doi:10.1371/journal.pone.0033597.g005
Figure 6. Effect of different treatments on apoptotic cascade.
KTC-1 cells were left untreated as controls (A), or treated with 20 MBq/
ml
131I( B), 5 mmol/L Bay 11-7082 (C) or combination (D) for 24 hours.
Then whole cell lysates were examined by Western blot for caspase 3
and PARP. In the second set of experiments, KTC-1 cells were treated
with no oligonucleotide control (E), scrambled oligonucleotides (F)o r
p65 siRNA transfection (G) first. Then these three groups of cells were
exposed to
131I (20 MBq/ml) for 24 hours (H–J). Caspase 3 and PARP
protein levels were examined by Western blot. b-actin was used as a
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apy or radiotherapy, synergism could be achieved [9,10,11,12].
Another approach of p65 siRNA transfection has been tried in
many types of cancers [15,23,24,25], and enhanced chemosensi-
tivity was demonstrated as well [15,23]. Yet, combined therapy
including p65 siRNA transfection has not been tested in thyroid
cancer so far.
In the current study, the effects of
131I on NF-kB function and
expression in DTC cells were analyzed first. DNA-binding assay
showed that NF-kB activation was dramatically increased at 6-
hour time point, reaching peaks at 24-hour time point for KTC-1
and WRO cells. Increased NF-kB reporter activation was also
proved by luciferase assay. However, these activations could be
significantly suppressed by a NF-kB inhibitor or by p65 siRNA
transfection. We then used Western blot data to show that
131I
could increase nuclear protein levels of NF-kB, while Bay 11-7082
or p65 siRNA transfection could dramatically inhibit NF-kB
protein levels.
NF-kB mediated anti-apoptosis are essentially depended on its
ability to enhance transcriptions of cell death suppressive genes
[7,18,26]. The most representative NF-kB controlled anti-
apoptotic factors are XIAP, cIAP1 and Bcl-xL, which can prevent
tumor cell killing effects [7,18]. XIAP can inhibit caspase 3 and 7,
and it is also involved in the suppression of the pro-apoptotic JNK
activity. cIAP1 is another potent inhibitor of apoptosis, which can
bind and inhibit caspase 3 and 8. And Bcl-xL is known to inhibit
cytochrome C release from mitochondria. In this investigation, we
found that XIAP, cIAP1 and Bcl-xL were significantly up-
Figure 7. Apoptotic changes measured by flow cytometry. The first set of experiments included four groups: KTC-1 cells received no
treatment (A), 20 MBq/ml
131I( B), 5 mmol/L Bay 11-7082 (C) or combination (D) for 24 hours. Then cells were harvested by trypsinization, double
stained by FITC-conjugated annexin V and propidium iodide, and then subjected for flow cytometry. In the second set of experiments, KTC-1 cells
were first treated with no oligonucleotide control (E), scrambled oligonucleotides (F) or p65 siRNA transfection (G). Then these three groups of cells
were exposed to
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131I. Inhibition of NF-kB by Bay 11-
7082 or by p65 siRNA transfection during
131I exposure could
change the balance toward significant down-regulation of these
factors.
Then, in order to confirm the possibility of synergistic effects
induced by combined therapies, we performed Western blot on
key apoptotic proteins and conducted flow cytometry to assess
apoptosis. Our results demonstrated significant synergy if NF-kB
was inhibited during
131I therapy. Our study also showed that NF-
kB pathway inhibition did not control iodine uptake, which
indicates its pro-apoptotic effects is the main mechanism for the
synergistic results.
Apoptosis is an essential process of eliminating destined cells
during development or after damage from chemotherapy or
radiotherapy. It is known that
131I-induced cell death can be both
apoptosis and necrosis, the nature of which is dose-dependent
[27]. Marx et al. [27] demonstrated that, in B-CPAP cells (another
DTC cell line), apoptosis was detectable after incubation with 1
MBq/ml of
131I for 2 days. At medium
131I activity concentration
(1–10 MBq/ml) apoptosis was predominant, while at much higher
131I activity concentration (especially higher than 100 MBq/ml)
necrosis became predominant. In our investigation, we used
131I
activity concentration of 20 MBq/ml, which could produce
enough apoptosis for different experiments. The slight dosage
difference could be from different cell lines and different
laboratory conditions.
Destruction of pro-apoptotic or anti-apoptotic balance is proved
to cause carcinogenesis. In cancer treatment settings, aberrant
apoptotic signaling could induce resistance to chemotherapy or
radiotherapy. Therefore, restoration of functional apoptosis in
cancer cells could be a useful approach to enhance therapeutic
efficacies. NF-kB pathway hypothesis has been tested true in
thyroid cancer already [9,10]. Increased NF-kB activity reinforces
the intrinsic therapy-resistance phenotype of thyroid cancer cells,
and its inhibition has been showing promising results in
combination with chemotherapy or radiotherapy [9,10]. The
present data adds to the hypothesis, that
131I could induce NF-kB
activation which attenuates
131I efficacy in thyroid cancer cells.
NF-kB inhibition is effective in suppressing
131I related NF-kB
induction and anti-apoptotic changes. In combined regimen
apoptosis can be achieved synergistically.
Author Contributions
Conceived and designed the experiments: ZM JT. Performed the
experiments: ZM SL KX QJ WZ. Analyzed the data: ZM SL QJ JT.
Contributed reagents/materials/analysis tools: ZM SL. Wrote the paper:
ZM SL JT.
Table 1. Synergy confirmed by Western blot and flow cytometry.
Western blot with semi-quantification* Flow cytometry
Caspase 3 p19 Caspase 3 p17 PARP p89 PARP p116
Annexin V positive
cells
Control 4.7260.69 4.4660.55 4.6560.70 93.02613.44 0.3660.18
131I(1) 25.6866.35 19.6463.89 32.7067.93 64.12610.14 9.9662.01
Bay 11-7082(2) 59.5368.55 41.2968.51 74.89611.90 45.6868.33 19.4364.29
Combined therapy(3) 103.74612.41 92.41610.97 101.53615.78 3.8460.55 49.9566.95
F (P)** 83.79 (,0.01) 85.06 (,0.01) 49.22 (,0.01) 47.43 (,0.01) 78.15 (,0.01)
P(1) : (3)*** ,0.01 ,0.01 ,0.01 ,0.01 ,0.01
P(2) : (3)*** ,0.01 ,0.01 ,0.05 ,0.01 ,0.01
*calculated by protein/b-actin with Quantity One Software;
**analyzed by one-way analysis of variance;
***analyzed by least significant difference test.
doi:10.1371/journal.pone.0033597.t001
Figure 8. Iodide uptake assay. (A) KTC-1 cells were left untreated or treated with Bay 11-7082 (5 mmol/L) for 24 hours. Then cells were cultured in
the present of Na
125I (37 KBq/mL) for 1 hour. Afterwards, the cells were washed and cell number was counted. Then radioactivity was measured. (B)
KTC-1 cells were treated with no oligonucleotide control, scrambled oligonucleotides or p65 siRNA transfection first. Then cells were exposed to
Na
125I, and radioactivity was measured. Similar results were obtained in three independent experiments.
doi:10.1371/journal.pone.0033597.g008
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